Semaglutide, lipid-lowering drugs, and NAFLD

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 5, 2017, Pages 329-330

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEMAGLUTIDE; TRIACYLGLYCEROL; URIC ACID; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; LIPID;

BODY MASS; FATTY ACID BLOOD LEVEL; HUMAN; HYPERURICEMIA; LETTER; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85018311331     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30109-2     Document Type: Letter

References (6)

1. 1 Sorli, C, Harashima, SI, Tsoukas, GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5 (2017), 251–260.
2. 2 Khavandi, M, Duarte, F, Ginsberg, HN, Reyes-Soffer, G, Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes. Curr Cardiol Rep, 19, 2017, 7.
3. 3 Katsiki, N, Mikhailidis, DP, Mantzoros, CS, Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.
4. 4 Katsiki, N, Papanas, N, Fonseca, VA, Maltezos, E, Mikhailidis, DP, Uric acid and diabetes: is there a link?. Curr Pharm Des 19 (2013), 4930–4937.
5. 5 Bedogni, G, Bellentani, S, Miglioli, L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 6, 2006, 33.
6. 6 Katsiki, N, Athyros, VG, Mikhailidis, DP, Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications 31 (2017), 521–522.